Svår vinter i Norge men Sverige är stabilt Omsättningen växte med 45% i Q1 men den organiska tillväx...
Framsteg med Imperative Care Corline meddelade under torsdagen att de ingått ett avtal med Imperativ...
Redeye comments on the recent news that TDC Net is to drop Huawei from DWDM networks by 2027 under t...
Innehavet i MFG har tyngt aktien och senaste förhandlingarna har fallit.
Redeye was hoping for a bit more in terms of growth, and so did Acuvi we believe.
Redeye considers BIMobject’s figures to be overall in line with our estimates.
Vaisala posted strong Q1 net sales above our expectations.
Suominen’s Q1 results remained weak. Earnings are to improve at some rate going forward, but valuati...
Redeye returns with an update following the Q1 report.
Spiffbet har publicerat sin delårsrapport för det första kvartalet 2023.
EBIT SEK 0.1m vs. ABGSCe -3.8m Non-woven & fiber technologies sales at SEK 17.
Boreo reported Q1 adjusted EBIT ex-PPA of EUR 2.1m, 13% above our estimate and 5% above Refinitiv co...
We raise '23e-'25e EBITA by 2% Cash flow generation is evident '23e EV/EBITA at ~8x Q1'23 report Th...
26.5% organic sales growth, EBITA margin reaches 7.
Strong on every single operational metric MFG is still in play 12x earnings without MFG potential A...
Redeye provides an initial take on Optomed’s Q1 2023 report.
Redeye comments on Enviro’s directed share issue of 150m shares, raising gross proceeds of SEK300m.
Redeye thinks Catella continues to perform decently in a very tough environment.
Redeye comments on Xspray Pharma following its Q1 2023 report.
Strong platform performance drove 19% org. growth Outlook remains strong – limited adj.
